StockData
Reviva Pharmaceuticals Holdings, Inc. logo

Reviva Pharmaceuticals Holdings, Inc. (RVPH) stock

RVPHOTCPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 13, 2026Score 2/30
$0.45−0.02 (-4.36%)

Close on Oct 19, 2026Market cap $5.94MP/E –Yield –

Reviva Pharmaceuticals operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Reviva Pharmaceuticals's operating income for the twelve months ending Sep 30, 2026 was -$11.88M. For fiscal 2025 it was -$20.20M. The highest annual figure on record is -$376.86K in fiscal 2019.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$20.20M–
FY2024Dec 31, 2024-$30.80M–
FY2023Dec 31, 2023-$39.50M–
FY2022Dec 31, 2022-$28.23M–
FY2021Dec 31, 2021-$10.10M–
FY2020Dec 31, 2020-$2.43M–
FY2019Dec 31, 2019-$376.86K–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026-$2.43M–
Q2 FY2026Jun 30, 2026-$2.62M–
Q1 FY2026Mar 31, 2026-$3.27M–
Q4 FY2025Dec 31, 2025-$3.56M–
Q3 FY2025Sep 30, 2025-$4.03M–
Q2 FY2025Jun 30, 2025-$6.07M–
Q1 FY2025Mar 31, 2025-$6.54M–
Q4 FY2024Dec 31, 2024-$6.28M–
Q3 FY2024Sep 30, 2024-$8.46M–
Q2 FY2024Jun 30, 2024-$8.13M–
Q1 FY2024Mar 31, 2024-$7.92M–
Q4 FY2023Dec 31, 2023-$9.62M–
Q3 FY2023Sep 30, 2023-$11.56M–
Q2 FY2023Jun 30, 2023-$11.34M–
Q1 FY2023Mar 31, 2023-$6.98M–
Q4 FY2022Dec 31, 2022-$8.89M–
Q3 FY2022Sep 30, 2022-$5.50M–
Q2 FY2022Jun 30, 2022-$5.52M–
Q1 FY2022Mar 31, 2022-$7.45M–
Q4 FY2021Dec 31, 2021-$3.96M–
Q3 FY2021Sep 30, 2021-$2.48M–
Q2 FY2021Jun 30, 2021-$1.79M–
Q1 FY2021Mar 31, 2021-$1.87M–
Q3 FY2020Nov 30, 2020-$352.01K–
Q2 FY2020Aug 31, 2020-$525.92K–
Q3 FY2019Nov 30, 2019-$166.02K–
Q2 FY2019Aug 31, 2019-$94.11K–
Q3 FY2018Nov 30, 2018-$79.15K–
Q2 FY2018Aug 31, 2018-$15.67K–

More Reviva Pharmaceuticals figures

See a number that looks wrong?